Sun Pharma Q1 FY27 Results: Profit Rises 27%, Revenue Grows 10.5%, Organon Acquisition On Track

Sun Pharmaceutical Industries reported its Q1 FY27 result, posting higher revenue and profit compared with the corresponding quarter last year. Consolidated net profit stood at ₹2,895 crore, up 27% from ₹2,279 crore in Q1 FY26. Revenue from operations increased 10.5% to ₹15,300 crore from ₹13,849 crore in the year-ago period.

The domestic business remained the company's strongest performer during the quarter. Sales from India formulations increased 16% to ₹5,475 crore, supported by steady demand across the portfolio. The API business also delivered double-digit growth, with revenue rising 10.5% to ₹597 crore. In overseas markets, emerging market formulations revenue stood at $311 million, while the rest of the world's business contributed $218 million.

Operating performance stayed healthy despite pressure on margins. Earnings before interest, tax, depreciation and amortisation (EBITDA) came in at ₹4,419 crore, while the EBITDA margin was 28.9%, lower than 31.1% in the same quarter last year.

Following the announcement of the Q1 FY27 result, Sun Pharmaceutical share price closed at ₹1,990.50, down 0.53% on the National Stock Exchange (NSE).

Sun Pharma Q1 FY27 Financial Performance

Sun Pharma reported year-on-year growth across its key financial metrics during June quarter.

*Previous year’s EBITDA is derived from the reported 2.7% year-on-year growth.

How Did Sun Pharma’s US Business Perform?

The US formulations business reported revenue of US$427 million during the June quarter, down 9.7% year-on-year, reflecting continued pressure in one of Sun Pharma's largest markets.

The company also booked a one-time loss of ₹204 crore during the quarter. At the same time, other income increased to ₹724 crore from ₹464 crore in the year-ago period, providing some support to the bottom line.

What Else Did Sun Pharma Announce?

Sun Pharma said shareholders of Organon have approved the proposed acquisition. The company expects the transaction to close in early 2027, subject to the remaining approvals.

Going ahead, investors are likely to watch whether the company can revive growth in the US market while maintaining the strong momentum seen in its India business.

Also Read - Zepto IPO: ₹1,000 Crore Pre-IPO Round Replaces Liting Plans For Now